CVS breakup plan reshapes healthcare giant

CVS Health plans to separate into two publicly traded companies by the first half of 2028, in a restructuring that will split its retail pharmacy operations from its insurance, pharmacy benefits and care delivery businesses. Under the plan, an independent CVS Pharmacy company will hold about 9,000 retail pharmacies, the company’s mail-order pharmacy and its walk-in MinuteClinics, while the remaining CVS Health entity will concentrate on health insurance, pharmacy benefits, specialty pharmacy services, primary care and home-based healthcare.

The CVS Health company will bring together Aetna, CVS Caremark, CVS Specialty, Oak Street Health and Signify Health. CVS describes the decision as the best long-term strategic option for its businesses and says the separation of a strong, independent CVS Pharmacy is intended to create more value for all stakeholders over time. The reorganization is scheduled to roll out in the first half of 2028, subject to customary conditions and regulatory steps.

The breakup follows years of criticism from officials in Louisiana and other states who argue that large healthcare conglomerates wield too much power over the prescription drug market. Regulators contend such companies control multiple links in the drug supply chain, keep pricing practices opaque and earn excessive profits, contributing to rising medication costs. Federal and state authorities have maintained pressure on vertically integrated healthcare groups over their role in drug pricing.

CVS acknowledges the regulatory environment as one factor in its review but emphasizes that it was only one among many considerations. The company states the restructuring is aimed at providing better, more affordable care to consumers, and at aligning each business with its strategic priorities. In 2025, CVS generated $402 billion in revenue, underscoring the scale of the enterprise being reshaped by the planned separation.

Analysts see the planned separation as consistent with the differing roles of CVS’s businesses. Retail pharmacy operations are viewed as contributing limited strategic value to Aetna and possessing different attributes from Aetna and the pharmacy benefit manager, which are both centered on cost containment. The spin-off is expected to sharpen management focus and simplify how investors evaluate risks tied to vertical integration.

At the same time, research notes point to potential dyssynergies once retail pharmacies are no longer under the same roof as the benefit manager, including reduced network steerage into CVS stores and lower pharmaceutical purchasing scale. These factors could create headwinds for both the retail pharmacy and pharmacy benefit manager units after the separation. Even so, the healthcare solutions side, including Aetna and Caremark specialty pharmacy, is described as holding considerable value at CVS Health’s current valuation multiples.

The announcement of the breakup and updated outlook prompted a mixed response in the stock market, with CVS Health shares declining in premarket trading as investors digested the softer expectations in some segments. Bernstein SocGen recently lowered its CVS Health price target to $106 while maintaining an Outperform rating, citing limited near-term catalysts but attractive exposure to a managed care turnaround and more stable earnings in retail pharmacy and the pharmacy benefit manager.

Other equity research firms have also adjusted their views, with Raymond James and Jefferies reducing their CVS Health price targets to $103 and keeping positive ratings. Bernstein SocGen estimates 18% upside even with the near-term uncertainty, highlighting the value of the Aetna and Caremark businesses relative to CVS Health’s valuation of about 10.6 times earnings. CVS plans to resume share repurchases in the fourth quarter after achieving its leverage goal ahead of schedule, adding a capital-return element as the company advances its multi-year restructuring.

The restructuring comes as CVS emphasizes its technology and artificial intelligence capabilities. The company has received industry recognition, including seven Stevie Awards, for responsible AI projects designed to improve care access, streamline prior authorization, identify bias and hallucinations in AI systems and support emergency logistics through drones. These initiatives are positioned alongside the structural separation as part of a broader strategic reset.

CVS is maintaining its full-year outlook while it prepares for the breakup and continues to develop its healthcare solutions and retail pharmacy platforms. Existing shareholders are expected to own shares in both CVS Health and CVS Pharmacy once the transaction is completed. Together, the separation plan, regulatory backdrop, analyst reassessments and technology investments are reshaping how investors and policymakers view the future of CVS Health.